Location of Repository

Generic exercise rehabilitation for patients with chronic obstructive pulmonary disease and chronic heart failure

By Rachael Andrea Evans

Abstract

Background: \ud Exertional breathlessness and fatigue are common disabling symptoms of patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Heart Failure (CHF). The mechanisms behind these symptoms are similar including skeletal muscle dysfunction. Exercise training at least partially reverses the skeletal muscle abnormalities and improves exercise performance and health related quality of life in both conditions. \ud Pulmonary rehabilitation, with exercise training as a core component, is an integral part of the management of COPD, but a service for CHF has not developed in the same way. The hypothesis, for the main studies described in this thesis, was that the successful model of pulmonary rehabilitation could be applied to patients with CHF and patients with COPD and CHF could be beneficially trained together. \ud Methods: \ud Two main studies were undertaken; \ud 1) a randomised controlled trial of pulmonary rehabilitation (PR) vs. normal care (NC) in patients with CHF \ud 2) a comparative observational study of PR between COPD and CHF. \ud \ud Alongside these studies, the outcome measures commonly used for COPD were applied to patients with CHF. Two pilot studies were performed investigating the effect of exercise training on other systemic manifestations of COPD and CHF. \ud Results: \ud Patients with CHF made significant improvements in exercise performance and health status with PR compared to NC. The improvements were similar to those seen in the patients with COPD. Measures of exercise performance and health status were applied successfully to patients with CHF. \ud Conclusions: \ud Patients with COPD and CHF can be successfully trained together demonstrating the feasibility of generic exercise rehabilitation for exertional breathlessness. Further work would need to investigate whether combined exercise programmes for COPD and CHF provides economies of scale for both populations. \ud The work in this thesis highlights the possibility of organising services for chronic disease around a disability rather than an individual disease

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/7559

Suggested articles

Preview

Citations

  1. (2005). [Can individualized rehabilitation improve functional independence in elderly patients with COPD?]. Rev Port Pneumol
  2. (2004). [Development of a Japanese version of the Modified Questionnaire on the Pulmonary Functional Status and Dyspnea]. Nihon Kokyuki Gakkai Zasshi
  3. (2006). [Maximal respiratory pressures and exercise tolerance in patients with COPD]. Pneumonol Alergol Pol
  4. (1997). [Reproducibility of measurements of blood gas exchange during exercise in mild cardiac failure: need for a preliminary test?]. Arch Mal Coeur Vaiss
  5. (1993). [Skeletal and respiratory muscle strength in chronic heart failure]. G Ital Cardiol
  6. (2001). [Strength of inspiratory muscles in chronic heart failure and chronic pulmonary obstructive disease]. Rev Med Chil
  7. (1992). 31Pnuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with chronic lung disease and congestive heart failure. Eur Respir J
  8. a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men.
  9. (2005). A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Serv Res
  10. (1995). A comparison of outpatient cardiac and pulmonary rehabilitation patients.
  11. (1999). A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest
  12. (2003). A comparison of the original chronic respiratory questionnaire with a standardized version. Chest
  13. (2001). A comparison of the shuttle and 6 minute walking tests with measured peak oxygen consumption in patients with heart failure.
  14. (2001). A comparison of three disease-specific and two generic health-status measures to evaluate the outcome of pulmonary rehabilitation in COPD. Respir Med
  15. (1982). A maximal multistage 20-m shuttle run test to predict VO2 max.
  16. (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax
  17. (1988). A new natriuretic peptide in porcine brain.
  18. (2007). A propensity matched study of New York Heart Association class and natural history end points in heart failure.
  19. (2001). A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax
  20. (2005). A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J
  21. (2002). A randomized controlled trial to evaluate the effect of informing patients about their pretreatment responses to two respiratory questionnaires. Chest
  22. (2003). A randomized, controlled trial comparing long-term and short-term exercise in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil
  23. (1999). A shuttle walk test for assessment of functional capacity in chronic heart failure. Am Heart J
  24. (1981). A study of short-term effect of rehabilitative therapy in chronic obstructive pulmonary disease. Respiration
  25. (2007). AACVPR/ACC/AHA
  26. (2005). Abdominal muscle and quadriceps strength in chronic obstructive pulmonary disease. Thorax
  27. (1986). Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation
  28. (1988). Abnormalities of skeletal muscle in patients with chronic heart failure.
  29. (2007). Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: a quantitative review. NMR Biomed
  30. (2006). ACSM's Guidelineds for Exercise Testing and Prescription. 7th edition,
  31. (2006). ACSM's Guidelines for Exercise Testing and Prescription. 7th edition.
  32. (2005). Adenine nucleotide loss in the skeletal muscles during exercise in chronic obstructive pulmonary disease. Thorax
  33. (2001). Age effect on transcript levels and synthesis rate of muscle MHC and response to resistance exercise.
  34. (1971). Alcoholic cardiomyopathy managed with prolonged bed rest. Ann Intern Med
  35. (1992). Alterations of skeletal muscle in chronic heart failure. Circulation
  36. (1999). Altered expression of myosin heavy chain in the vastus lateralis muscle in patients with COPD. Eur Respir J
  37. (1991). Altered skeletal muscle metabolic response to exercise in chronic heart failure. Relation to skeletal muscle aerobic enzyme activity. Circulation
  38. (2008). Am Coll Cardiol
  39. (1970). Ambulatory care for emphysema and chronic bronchitis. Chest
  40. (2006). American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med
  41. (2008). AMPK and PPARdelta agonists are exercise mimetics. Cell
  42. (1999). An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax
  43. (2007). and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
  44. (1990). and without chronic respiratory failure.
  45. (2008). Anemia and mortality in heart failure patients a systematic review and meta-analysis.
  46. (2003). Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation
  47. (2004). Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  48. (2007). Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement.
  49. (2003). Antiinflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure.
  50. (2005). Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation
  51. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure
  52. (2008). Anxiety and depression in end-stage COPD. Eur Respir J
  53. (2002). apoptosis and cachexia: the potential for TNF antagonism.
  54. (2000). Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart
  55. (2001). Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine.
  56. (1997). Appendicular skeletal muscle mass: effects of age, gender, and ethnicity.
  57. (1989). Approaches to rehabilitation of patients with ventilatory insufficiency.
  58. (2008). Are patients with COPD more active after pulmonary rehabilitation? Chest
  59. (2006). Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes
  60. (1985). Assessment of transdiaphragmatic pressure in humans.
  61. (2004). Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  62. (2008). Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil
  63. (2002). ATS statement: guidelines for the six-minute walk test.
  64. (2003). ATS/ACCP Statement on cardiopulmonary exercise testing.
  65. (1997). Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation
  66. (2000). Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure.
  67. (2004). Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects.
  68. (2002). Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J
  69. (1995). Benefit of selective respiratory muscle training on exercise capacity in patients with chronic congestive heart failure. Circulation
  70. (1991). Benefits of a multidisciplinary pulmonary rehabilitation program. Improvements are independent of lung function. Chest
  71. (2003). Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med
  72. (2004). Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NTproBNP). Clin Chem Lab Med
  73. (2000). Biological quality control for exercise testing. Thorax
  74. (1998). Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med
  75. (2009). BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA
  76. (1997). Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure.
  77. (2006). Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med
  78. (2004). Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure.
  79. (2002). brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure.
  80. (2002). British lung foundation. http://www.lunguk.org/Resources/British%20Lung%20Foundation/Migrated% 20Resources/Documents/B/BLF_pul_rehab_survey.pdf .
  81. (2005). Can individualized rehabilitation improve functional independence in elderly patients with COPD? Chest
  82. (1999). Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations.
  83. (1999). Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest
  84. (2009). Cardiac cachexia: A systematic overview. Pharmacol Ther
  85. (2008). Cardiopulmonary exercise test characteristics in patients with chronic obstructive pulmonary disease and associated pulmonary hypertension. Respiration
  86. (2000). Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J
  87. (2002). Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure patients. Chest
  88. (2003). Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest
  89. (1997). Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease.
  90. (2007). Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD. Thorax
  91. (2003). Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation
  92. (1996). Changes in myofibrillar protein composition of human diaphragm elicited by congestive heart failure.
  93. (2005). Changes in myosin heavy chain mRNA and protein expression in human skeletal muscle with age and endurance exercise training.
  94. (2005). Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  95. (1997). Chronic congestive heart failure elicits adaptations of endurance exercise in diaphragmatic muscle. Circulation
  96. (2008). Chronic heart failure and chronic obstructive pulmonary disease: one problem, one solution?
  97. (2004). Chronic obstructive pulmonary disease and chronic heart failure: two muscle diseases? J Cardiopulm Rehabil
  98. (2008). Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J
  99. (2005). Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.
  100. (1998). Chronic obstructive pulmonary disease: capillarity and fiber-type characteristics of skeletal muscle.
  101. (2006). Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc
  102. (2002). Circulating brain natriuretic peptide values in healthy men before and after exercise. Metabolism
  103. (2003). Circulation
  104. (2006). Clerico A et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure.
  105. (1995). Clinical assessment of the respiratory muscles. Phys Ther
  106. (2004). Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.
  107. (2003). Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report.
  108. (2004). Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J
  109. (2008). Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. Eur Heart J
  110. (2004). Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J
  111. (2004). Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ
  112. (2008). Comorbidity in patients undergoing coronary artery bypass graft surgery: impact on outcome and implications for cardiac rehabilitation. Eur J Cardiovasc Prev Rehabil
  113. (2002). Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  114. (1999). Comparison of functional state between bilateral lung volume reduction surgery and pulmonary rehabilitation: a six-month followup study.
  115. (1997). Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax
  116. (1994). Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J
  117. (2004). Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure.
  118. (2002). Comparison of the peak exercise response measured by the ramp and 1-min step cycle exercise protocols in patients with exertional dyspnea. Chest
  119. (1980). Computerized tomographic determination of human thigh components. The effects of immobilization in plaster and subsequent physical training.
  120. (2008). Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNFalpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol. Kardiol Pol
  121. (2005). Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  122. (2003). Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  123. (1999). Contribution of lung function to exercise capacity in patients with chronic heart failure. Respiration
  124. (2000). Contribution of skeletal muscle 'ergoreceptors' in the human leg to respiratory control in chronic heart failure.
  125. (1995). Contribution of the respiratory muscles to the lactic acidosis of heavy exercise in COPD. Chest
  126. (1999). controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation
  127. (1980). Controlled trial of supervised exercise training in chronic bronchitis.
  128. (2005). Coordinated changes in mitochondrial function and biogenesis in healthy and diseased human skeletal muscle.
  129. (2008). Cordoba-Lanus E, Muros dF et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest
  130. (2006). Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients.
  131. (2006). Creactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax
  132. (2005). Creactive protein in heart failure: prognostic value and the effect of valsartan. Circulation
  133. (1995). Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res
  134. (2008). Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax
  135. (1999). Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J
  136. (1993). Daily physical activity levels in congestive heart failure.
  137. (1999). De Suso JM, Moreno A et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  138. (2004). de Vries WR et al. Determinants of maximal exercise performance in chronic heart failure. Eur J Cardiovasc Prev Rehabil
  139. (1991). Depressed aerobic enzyme activity of skeletal muscle in severe chronic heart failure.
  140. (2003). Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles.
  141. (1988). Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance.
  142. (2006). Determination of exercise training heart rate in patients on beta-blockers after myocardial infarction. Eur J Cardiovasc Prev Rehabil
  143. (1989). Development and testing of a new measure of health status for clinical trials in heart failure.
  144. (1998). Development and testing of the modified version of the pulmonary functional status and dyspnea questionnaire (PFSDQM). Heart Lung
  145. (2001). Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax
  146. (1992). Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax
  147. (2007). Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med
  148. (1997). Diaphragm performance during maximal voluntary ventilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  149. (1996). Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  150. (2000). Diaphragmatic fatigue and highintensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  151. (2005). Dietary problems in patients with severe chronic obstructive pulmonary disease.
  152. (2006). Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem
  153. (1991). Direct measurement of skeletal muscle fatigue in patients with chronic heart failure. Br Heart J
  154. (2004). Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass.
  155. (2004). Does aerobic training lead to a more active lifestyle and improved quality of life in patients with chronic heart failure? Eur J Heart Fail
  156. (1991). Does chronic hypoxaemia induce transformations of fibre types? Acta Physiol Scand
  157. (2004). Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med
  158. (2001). Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J
  159. (2008). Economic burden of heart failure in the elderly. Pharmacoeconomics
  160. (2007). Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA
  161. (2007). Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebocontrolled trial.
  162. (2007). Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ
  163. (2006). Effect of physical training on exercise capacity, gas exchange and N-terminal pro-brain natriuretic peptide levels in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil
  164. (2004). Effects of a home walking exercise program on functional status and symptoms in heart failure. Am Heart J
  165. (2002). Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J
  166. (2007). Effects of calcium supplementation on bone loss and fractures in congestive heart failure.
  167. (1983). Effects of disuse on the structure and function of skeletal muscle. Med Sci Sports Exerc
  168. (1997). Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure.
  169. (1995). Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J
  170. (2002). Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J
  171. (2006). Effects of exercise training on cardiac performance, exercise capacity and quality of life in patients with heart failure: a meta-analysis. Eur J Heart Fail
  172. (2000). Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA
  173. (2008). Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med
  174. (1992). Effects of increased inspired oxygen concentrations on exercise performance in chronic heart failure. Lancet
  175. (1990). Effects of physical training in chronic heart failure. Lancet
  176. (1974). Effects of physical training on hemodynamics and pulmonary function at rest and during exercise in patients with chronic obstructive pulmonary disease. Chest
  177. (1995). Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med
  178. (1991). Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J
  179. (1998). Effects of sampling interval on peak oxygen consumption in patients evaluated for heart transplantation. Chest
  180. (1998). Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med
  181. (1996). Effects of short-term exercise training and activity restriction on functional capacity in patients with severe chronic congestive heart failure.
  182. (1999). Effects of short-term exercise training in patients with heart failure. Folia Med (Plovdiv )
  183. (2004). Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  184. (2004). Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J
  185. (2000). Effects of unweighting and clenbuterol on myosin light and heavy chains in fast and slow muscles of rat.
  186. (2009). Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA
  187. (2005). Elecsys NT-ProBNP and BNP assays: are there analytically and clinically relevant differences?
  188. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
  189. (2007). Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease. Lung
  190. (1999). Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med
  191. (2001). Endothelial dysfunction in patients with chronic heart failure: systemic effects of lowerlimb exercise training.
  192. (2004). Endurance and strength training in patients with COPD. Chest
  193. (1986). Endurance training in rats with chronic heart failure induced by myocardial infarction. Circulation
  194. (2004). Essential biochemistry and physiology of (NT-pro)BNP.
  195. (1986). Evaluating the effects of chronic therapy in patients with irreversible air-flow obstruction. Am Rev Respir Dis
  196. (1988). Evaluation of clinical methods for rating dyspnea. Chest
  197. (1985). Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation
  198. (1996). Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax
  199. (2003). Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation
  200. (2004). Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev
  201. (1996). Exercise capacity in heart failure patients: relative importance of heart and skeletal muscle. Clin Physiol
  202. (2005). Exercise hyperventilation in chronic heart failure is not caused by systemic lactic acidosis.
  203. (2003). Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle.
  204. (2005). Exercise outcomes after pulmonary rehabilitation depend on the initial mechanism of exercise limitation among non-oxygen-dependent COPD patients. Chest
  205. (1990). Exercise reconditioning in the rehabilitation of patients with chronic obstructive pulmonary disease: a short- and long-term analysis. Arch Phys Med Rehabil
  206. (1982). Exercise responses before and after physical conditioning in patients with severely depressed left ventricular function.
  207. (2001). Exercise testing and interpretation. A practical approach. Cambridge university press,
  208. (1997). Exercise testing and training of patients with heart failure due to left ventricular systolic dysfunction. J Cardiopulm Rehabil
  209. (2005). Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax
  210. (2005). Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest
  211. (1989). Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation
  212. (2003). Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size. A retrospective analysis of the Leipzig Heart Failure Training Trial. Eur J Cardiovasc Prev Rehabil
  213. (1988). Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation
  214. (2002). Exercise training increases lipid metabolism gene expression in human skeletal muscle.
  215. (2004). Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ
  216. (2007). Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol.
  217. (2003). Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  218. (1995). Exhaustive treadmill exercise does not reduce twitch transdiaphragmatic pressure in patients with COPD. Am J Respir Crit Care Med
  219. (1976). Feasibility of physical training after myocardial infarction and its effect on return to work, morbidity and mortality. Acta Med Scand Suppl
  220. (2004). Fredenrich A et al. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie
  221. (2007). Free radical-mediated skeletal muscle dysfunction in inflammatory conditions.
  222. (2004). Functional and morphological skeletal muscle abnormalities correlate with reduced electromyographic activity in chronic heart failure. Eur J Cardiovasc Prev Rehabil
  223. (1993). Functional capacity in heart failure. Comparison of methods for assessment and their relation to other indexes of heart failure. The V-HeFT VA Cooperative Studies Group. Circulation
  224. (1979). Functional evaluation of a physical rehabilitation program including breathing exercises and bicycle training in chronic obstructive lung disease. Respiration
  225. (2006). Functional status and quality of life in chronic obstructive pulmonary disease.
  226. (2000). Functional status and survival following pulmonary rehabilitation. Chest
  227. (2007). Gabutti A et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. Clin Chem
  228. (1987). Grading of dyspnoea and walking speed in cardiac disease and in chronic airflow obstruction.
  229. (1995). Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J
  230. (1975). Haas A et al. Chronic obstructive airway diseases. Current concepts in diagnosis and comprehensive care. JAMA
  231. (2007). Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J
  232. (2004). Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta
  233. (2003). Health status measurement: sensitivity of the self-reported Chronic Respiratory Questionnaire (CRQ-SR) in pulmonary rehabilitation. Thorax
  234. (2001). Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J
  235. (2001). Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. Clin Physiol
  236. (1999). Heart failure-related myopathy. Clinical and pathophysiological insights. Eur Heart J
  237. (1990). Heightnormalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status.
  238. (2006). Hetherington A et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure.
  239. (2003). Hindlimb unloading increases oxidative stress and disrupts antioxidant capacity in skeletal muscle. Free Radic Biol Med
  240. (1998). Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc
  241. (1997). Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation
  242. (2006). How long should outpatient pulmonary rehabilitation be? A randomised controlled trial of 4 weeks versus 7 weeks. Thorax
  243. http://www.who.int/bmi/index.jsp?introPage=intro_3.html . 1-9-2006. 7-2-2009. Ref Type: Electronic Citation
  244. (2006). Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure.
  245. (2002). Impact of heart failure and left ventricular systolic dysfunction on quality of life: a crosssectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J
  246. (1999). Impaired pulmonary diffusion during exercise in patients with chronic heart failure. Circulation
  247. (1998). Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients. Chest
  248. (1998). Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation
  249. (2005). Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest
  250. (1997). Increase in percutaneous muscle biopsy yield with a suction-enhancement technique.
  251. (1994). Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. Br Heart J
  252. (2008). Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax
  253. (2006). Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol
  254. (2004). Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation
  255. (2003). Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J
  256. (2001). Incremental shuttle walk test in the assessment of patients for heart transplantation. Heart
  257. (2005). Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. Am Heart J
  258. (2001). Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure.
  259. (2000). Influence of work rate incremental rate on the exercise responses in patients with COPD. Med Sci Sports Exerc
  260. (2004). Inspiratory muscle load and capacity in chronic heart failure. Thorax
  261. (2007). Inspiratory muscle strength in chronic obstructive pulmonary disease depending on disease severity. Clin Sci (Lond)
  262. (2008). Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. Respir Med
  263. (2004). Inspiratory muscle training using an incremental endurance test alleviates dyspnea and improves functional status in patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil
  264. (1992). Inspiratory muscle weakness and dyspnea in chronic heart failure. Am Rev Respir Dis
  265. (2005). Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart
  266. (1997). Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med
  267. (2003). Invited review: Aging and sarcopenia.
  268. (2004). Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure? Am Heart J
  269. (2001). Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. Chest
  270. (2007). Is strength training the more efficient training modality in chronic heart failure? Med Sci Sports Exerc
  271. (2003). Isometric muscle force measurement for clinicians treating patients with osteoarthritis of the knee. Arthritis Rheum
  272. (1981). Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure.
  273. (2000). Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study.
  274. (1996). Leg blood flow, metabolism and exercise capacity in chronic stable heart failure.
  275. (2007). Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart
  276. (1979). Long-term effects of physical training on coronary patients with impaired ventricular function. Circulation
  277. (2006). Long-term versus intermediate-term supervised exercise training in advanced heart failure: effects on exercise tolerance and mortality.
  278. (2000). Longterm effects of outpatient rehabilitation of COPD: A randomized trial. Chest
  279. (2006). Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab Res Rev
  280. (2008). Lower limb activity and its determinants in COPD. Thorax
  281. (1994). Lung
  282. (2003). Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med
  283. (2001). Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med
  284. (2007). Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients.
  285. (1991). Maximum intensity exercise training in patients with chronic obstructive pulmonary disease. Chest
  286. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials
  287. (2006). Measuring body composition in chronic heart failure: a comparison of methods.
  288. (1993). Measuring health-related quality of life.
  289. (2007). Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. Eura Medicophys
  290. (1995). Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease.
  291. (2007). Metabolic Functions of Peroxisome ProliferatorActivated Receptor beta/delta in Skeletal Muscle. PPAR Res
  292. (2002). Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  293. (2003). Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. Kidney Int
  294. (2001). Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation
  295. (1998). Muscle fibre atrophy in critically ill patients is associated with the loss of myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol Appl Neurobiol
  296. (2007). Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax
  297. (2002). Muscle mass, not body weight, predicts outcome in patients with chronic obstructive pulmonary disease.
  298. (2000). Muscle metabolic status in patients with severe COPD with and without long-term prednisolone. Eur Respir J
  299. (2004). Muscle strength as a predictor of long-term survival in severe congestive heart failure.
  300. (1998). Muscle unloading induces slow to fast transitions in myofibrillar but not mitochondrial properties. Relevance to skeletal muscle abnormalities in heart failure.
  301. (1997). Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J
  302. (2006). Myeloperoxidase and Creactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J
  303. (2003). N-terminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J
  304. (1999). Neuroendocrine activation in heart failure is modified by endurance exercise training.
  305. (2005). Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest
  306. (1998). Neuropeptide secretion in exercise. Neuropeptides
  307. (2003). Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax
  308. (1997). Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation
  309. (2008). Nuclear factor-kappa B signaling in skeletal muscle atrophy.
  310. (2003). Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomised controlled trial. Thorax
  311. (2003). Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta
  312. (2004). Obesity and suppressed B-type natriuretic peptide levels in heart failure.
  313. (1987). On measuring repeatability of data from selfadministered questionnaires.
  314. (1991). Operation Everest II: structural adaptations in skeletal muscle in response to extreme simulated altitude. Acta Physiol Scand
  315. (2008). Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure.
  316. (2006). Orphan nuclear receptors: therapeutic opportunities in skeletal muscle.
  317. (2003). Osteoporosis in chronic obstructive pulmonary disease.
  318. (2005). Outcome of exercise training on the long-term burden of hospitalisation in patients with chronic heart failure. A retrospective study.
  319. (2007). Oxidative stress in chronic obstructive pulmonary disease patients submitted to a rehabilitation program. Respir Med
  320. (2007). Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol
  321. (2007). Oxygen therapy during exercise training in chronic obstructive pulmonary disease. Cochrane Database Syst Rev
  322. (2005). Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation
  323. (1970). Perceived exertion as an indicator of somatic stress.
  324. (1998). Perception of fatigue and quality of life in patients with COPD. Chest
  325. (1975). Percutaneous needle biopsy of skeletal muscle in physiological and clinical research.
  326. (2003). Performing at extreme altitude: muscle cellular and subcellular adaptations.
  327. (2003). Peripheral muscle strength training in bed-bound patients with COPD receiving mechanical ventilation: effect of electrical stimulation. Chest
  328. (2001). Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med
  329. (1996). Peripheral muscle weakness contributes to exercise limitation in COPD.
  330. (1998). Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  331. (2003). Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability.
  332. (2008). Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle.
  333. (2007). Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J
  334. (2003). Peroxisome proliferator-activated receptorgamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev
  335. (2008). Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Eur Respir J
  336. (2008). PGC-1alpha is not mandatory for exercise- and training-induced adaptive gene responses in mouse skeletal muscle.
  337. (1971). Physical activity and the prevention of coronary heart disease. Ann Clin Res
  338. (1977). Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home. Thorax
  339. (2002). Physical training for bronchiectasis. Cochrane Database Syst Rev
  340. (2008). Physical training for interstitial lung disease. Cochrane Database Syst Rev
  341. (1993). Physical training improves skeletal muscle metabolism in patients with chronic heart failure.
  342. (2007). Physical training in patients with chronic heart failure of ischemic origin: effect on exercise capacity and left ventricular remodeling. Eur J Cardiovasc Prev Rehabil
  343. (2001). Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J
  344. (2007). Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest
  345. (1997). Physiological abnormalities of skeletal muscle in dialysis patients. Nephrol Dial Transplant
  346. (1997). placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet
  347. (2005). Poor relationship between exercise capacity and spirometric measurements in patients with more symptomatic heart failure.
  348. (2004). Predicting maximum heart rate among patients with coronary heart disease receiving betaadrenergic blockade therapy. Am Heart J
  349. (2008). Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure.
  350. (1994). Predictors of exercise capacity in chronic heart failure. Eur Heart J
  351. (2007). Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238. J Thorac Oncol
  352. (2001). Preservation of exercise capacity and lack of peripheral changes in asymptomatic patients with severely impaired left ventricular function. Eur Heart J
  353. (1993). Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis
  354. (1989). Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
  355. (2006). Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases.
  356. (2006). Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med
  357. (1994). Principles of exercise testing and interpretation.
  358. (2003). Prognostic predictors for survival in patients with COPD using cardiopulmonary exercise testing. Clin Physiol Funct Imaging
  359. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT
  360. (1972). Prolonged bed rest in the treatment of idiopathic cardiomyopathy.
  361. (1971). Prolonged bed rest in the treatment of ischemic cardiomyopathy. Chest
  362. (2006). Psychological outcomes of an outpatient pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med
  363. (1982). Psychophysical bases of perceived exertion. Med Sci Sports Exerc
  364. (2005). Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary disease. Arch Phys Med Rehabil
  365. (2005). Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc
  366. (2007). Pulmonary function changes associated with cardiomegaly in chronic heart failure.
  367. (1999). Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J
  368. (2006). Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev
  369. (1992). Pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD) with recommendations for its use. Report of the European Respiratory Society Rehabilitation and Chronic Care Scientific Group (S.E.P.C.R. Rehabilitation Working Group). Eur Respir J
  370. (2005). Pulmonary rehabilitation in chronic obstructive pulmonary disease.
  371. (2009). Pulmonary rehabilitation is successful for COPD irrespective of MRC dyspnoea grade. Respir Med
  372. (2004). Pulmonary rehabilitation: analysis of a clinical service. Physiother Res Int
  373. (2007). Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest
  374. (2004). Quadriceps muscle endurance in patients with chronic obstructive pulmonary disease. Muscle Nerve
  375. (2007). Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax
  376. (2005). Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest
  377. (2005). quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  378. (1996). Quality of life and cardiorespiratory function in chronic heart failure: effects of 12 months' aerobic training. Heart
  379. (2006). Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J
  380. (1991). Radaelli A et al. Angiotensin-converting enzyme inhibition and physical training in heart failure.
  381. (2006). Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax
  382. (2005). Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure.
  383. (1981). Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax
  384. (1994). Randomised controlled trial of respiratory rehabilitation. Lancet
  385. (1992). Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation. Thorax
  386. (2008). Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  387. (2001). Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure.
  388. (2007). Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail
  389. (2005). Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ
  390. (1995). Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation
  391. (2007). Reduced mitochondrial density in the vastus lateralis muscle of patients with COPD. Eur Respir J
  392. (2006). Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation
  393. (1991). Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis
  394. (2008). Ref Type: Generic
  395. (1998). Reference equations for the six-minute walk in healthy adults.
  396. (2003). Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate.
  397. (1999). Reference values for concentric knee isokinetic strength and power in nonathletic men and women from 20 to 80 years old. J Orthop Sports Phys Ther
  398. (1998). Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation
  399. (2004). Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol
  400. (1967). Rehabilitation after myocardial infarction: practical experience with a graded exercise program. Can Med Assoc J
  401. (1960). Rehabilitation in congestive heart failure. Circulation
  402. (1959). Rehabilitation of patients with chronic pulmonary disease. Med Clin North Am
  403. (2002). Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet
  404. (1997). Relation of daily activity levels in patients with chronic heart failure to long-term prognosis.
  405. (2007). Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respir Med
  406. (2004). Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J
  407. (1994). Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax
  408. (2004). Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc
  409. (2005). Reliability of a single-session isokinetic and isometric strength measurement protocol in older men.
  410. (2003). repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir Med
  411. (2008). Reproducibility and safety of the incremental shuttle walking test for cardiac rehabilitation.
  412. (1998). Reproducibility of cardiopulmonary exercise testing in elderly patients with congestive heart failure.
  413. (1989). Reproducibility of incremental maximal cycle ergometer tests in patients with mild to moderate obstructive lung diseases. Lung
  414. (2008). Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing).
  415. (2003). Reproducibility of the measurement of the muscle ergoreflex activity in chronic heart failure.
  416. (1985). Reproducibility of VO2max in patients with chronic air-flow obstruction. Am Rev Respir Dis
  417. (1999). Resistance exercise training increases muscle strength, endurance, and blood flow in patients with chronic heart failure.
  418. (2002). Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J
  419. (1953). Respiratory exercises for chronic pulmonary emphysema. Bull Johns Hopkins Hosp
  420. (2001). Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation
  421. (1992). Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation
  422. (2005). Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. Respir Res
  423. (2000). Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet
  424. (2006). Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. J Cardiopulm Rehabil
  425. (2003). Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax
  426. (2008). Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax
  427. (2005). Role of oxidativenitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol
  428. (1999). Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE). Eur Heart J
  429. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
  430. (1992). Sherbourne CD. The MOS 36-item short-form health survey (SF36). I. Conceptual framework and item selection. Med Care
  431. (1993). Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ
  432. (2008). Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax
  433. (1997). Short-term reproducibility of cardiopulmonary measurements during exercise testing in patients with severe chronic heart failure. Am Heart J
  434. (1985). Should study subjects see their previous responses? J Chronic Dis
  435. (2000). Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure.
  436. (1996). Shuttle walking test: a new approach for evaluating patients with pacemakers. Heart
  437. (1998). Shuttle-walk test to assess chronic heart failure. Lancet
  438. (2005). Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients.
  439. (2005). Six minute walk test.
  440. (2007). Sixminute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease. Thorax
  441. (1996). Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease.
  442. (1996). Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J
  443. (2000). Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives.
  444. (2007). Skeletal muscle dysfunction in patients with idiopathic pulmonary arterial hypertension. Respir Med
  445. (1976). Skeletal muscle enzymes and fiber composition in male and female track athletes.
  446. (2007). Skeletal muscle ergoreflex overactivity is not related to exercise ventilatory inefficiency in nonhypoxaemic patients with COPD.
  447. (1995). Skeletal muscle fiber composition and capillarization in patients with chronic heart failure: relation to exercise capacity and central hemodynamics.
  448. (2002). Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J
  449. (1997). Skeletal muscle function and its relation to exercise tolerance in chronic heart failure.
  450. (1992). Skeletal muscle function, morphology, and metabolism in patients with congestive heart failure. Chest
  451. (2005). Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J
  452. (1993). Skeletal muscle metabolism during exercise and recovery in patients with respiratory failure. Thorax
  453. (1996). Skeletal muscle metabolism during exercise in patients with chronic heart failure. Heart
  454. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease
  455. (1997). Skeletal muscle myosin heavy-chain synthesis rate in healthy humans.
  456. (1990). Skeletal muscle response to exercise training in congestive heart failure.
  457. (1993). Skeletal muscle size: relationship to muscle function in heart failure.
  458. (2000). Skeletal muscle strength and endurance in patients with mild COPD and the effects of weight training.
  459. (2002). Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with Btype natriuretic peptide. Am Heart J
  460. (1986). Statistical methods for assessing agreement between two methods of clinical measurement. Lancet
  461. (1998). Statistical power analysis for the behavioural sciences. 2nd ed.
  462. (1980). Strength of isometric and isokinetic contractions: knee muscles of men aged 20 to 86. Phys Ther
  463. (2002). Strength/endurance training versus endurance training in congestive heart failure. Med Sci Sports Exerc
  464. (2003). Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest
  465. (2006). Study protocol to investigate the effects of testosterone therapy as an adjunct to exercise rehabilitation in hypogonadal males with chronic heart failure. BMC Cardiovasc Disord
  466. (2007). Supervised high intensity continuous and interval training vs. self-paced training in COPD. Respir Med
  467. (2000). Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax
  468. (1996). Symptom intensity and subjective limitation to exercise in patients with cardiorespiratory disorders. Chest
  469. (2003). Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
  470. (2005). Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail
  471. (2007). Symptoms of fatigue in chronic heart failure patients: clinical and psychological predictors.
  472. (2007). Test-retest of a Swedish version of the Pulmonary Functional Status & Dyspnea Questionnaire-modified. Scand J Occup Ther
  473. (1999). Test-retest reliability of symptom-limited cycle ergometer tests in patients with chronic obstructive pulmonary disease. Nurs Res
  474. (2006). Testosterone therapy in men with moderate severity heart failure: a doubleblind randomized placebo controlled trial. Eur Heart J
  475. (2004). The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
  476. (2003). The burden of illness and economic evaluation for COPD. Eur Respir J Suppl
  477. (2005). The contribution of peripheral muscle function to shuttle walking performance in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil
  478. (2002). The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr
  479. (1994). The Criteria Committee of the New York Heart Association.
  480. (1984). The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease.
  481. (2009). The Dose Effect of Pulmonary Rehabilitation on Physical Activity, Perceived Exertion, and Quality of Life. J Cardiopulm Rehabil Prev
  482. (2008). The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med
  483. (2003). The effect of ageing and immobilization on structure and function of human skeletal muscle fibres.
  484. (2007). The effect of cardiac rehabilitation on quality of life, anxiety and depression in patients with congestive heart failure. A randomized controlled trial, short-term results. Eura Medicophys
  485. (1998). The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J
  486. (1971). The effect of prolonged bed rest on postpartal cardiomyopathy. Am Heart J
  487. (2000). The effect of salbutamol on skeletal muscle in chronic heart failure.
  488. (1999). The effect of specific inspiratory muscle training on the sensation of dyspnea and exercise tolerance in patients with congestive heart failure. Clin Cardiol
  489. (2004). The effect of the beta2-adrenoceptor agonist prodrug BRL-47672 on cardiovascular function, skeletal muscle myosin heavy chain, and MyoD expression in the rat. J Pharmacol Exp Ther
  490. (2005). The effectiveness of different combinations of pulmonary rehabilitation program components: a randomized controlled trial. Chest
  491. (1990). The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure.
  492. (2003). The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial.
  493. (1999). The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax
  494. (1999). The ergoreflex in patients with chronic stable heart failure.
  495. (2002). The incremental shuttle walking test in elderly people with chronic airflow limitation. Thorax
  496. (2008). The minimum clinically important improvement for the Incremental Shuttle Walking Test. Thorax
  497. (1994). The MOS 36-item ShortForm Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care
  498. (2006). The mRNA expression profile of metabolic genes relative to MHC isoform pattern in human skeletal muscles.
  499. (2004). The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem
  500. (2006). The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab
  501. (1990). The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels. Am Rev Respir Dis
  502. (1993). The Physical Activity Scale for the Elderly (PASE): development and evaluation.
  503. (2007). The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure.
  504. (2007). The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J
  505. (1984). The respiratory muscles in COPD. State of the art. Chest
  506. (2003). The shuttle walk exercise test in idiopathic pulmonary fibrosis. Respir Med
  507. (1959). The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J
  508. (2006). Thigh muscle strength and endurance in patients with COPD compared with healthy controls. Respir Med
  509. (2005). Time of day influences the environmental effects on muscle force and contractility. Med Sci Sports Exerc
  510. (1997). Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. Eur Respir J
  511. (1985). Trends in acute coronary heart disease mortality, morbidity, and medical care from
  512. (1997). Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting.
  513. (1994). Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.
  514. (1976). Twelve-minute walking test for assessing disability in chronic bronchitis.
  515. (1992). Use of limb movement sensors as indicators of the level of everyday physical activity in chronic congestive heart failure.
  516. (1999). Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax
  517. (2002). Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung
  518. (1997). Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet
  519. (1991). Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation
  520. (1991). Variability of breathlessness measurement in patients with chronic obstructive pulmonary disease. Chest
  521. (1985). ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease. Thorax
  522. (2009). Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med
  523. (2008). Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease.
  524. (2007). Walking distance is a predictor of exacerbations in patients with chronic obstructive pulmonary disease. Respir Med
  525. (1997). Wasting as independent risk factor for mortality in chronic heart failure. Lancet
  526. (1998). Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.
  527. (2002). ZuWallack RL. An evaluation of two approaches to exercise conditioning in pulmonary rehabilitation. Chest

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.